Rocket Pharmaceuticals, Inc. (RCKT) Stock Price & Analysis

Rocket Pharmaceuticals, Inc. (RCKT) is trading at USD 2.2, down 4.77% today, as of October 23, 2026 at 14:20 UTC (US market open; quotes may be delayed), according to Nexqual market data.

RCKT last closed at USD 2.31; today's session has ranged USD 2.17–2.27 on volume of 570,117 shares. Market capitalization is $241.50M, with a 52-week range of USD 2.17–5.45 (NGM). Source: Nexqual, retrieved October 23, 2026 at 14:20 UTC.

Also available as compact Markdown for AI agents: nexqual.com/RCKT.md

Key facts (RCKT)

• Last four reported quarters (through Jun 30, 2026): revenue $0K, net income -$17.3M, free cash flow -$170M (SEC filings).
• 1 of 80 tracked superinvestors hold RCKT (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
• Insider open-market sales, last ~7 months: 15 Form 4 filings, $708K; 15 not under a Rule 10b5-1 plan ($708K); 0 by opportunistic insiders, 7 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Hold (mean 2.57 on a 1–5 scale) (14 analysts), mean target USD 8.58 (range 2.95–15).
• Total return with dividends: 1Y -41.2% vs S&P 500 +14.4%; 5Y -92.6% vs S&P 500 +77.0%.
• Next earnings: 2026-11-05, EPS estimate USD -0.41, revenue estimate $182K.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (RCKT)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (RCKT)

P/B 0.7x · FCF yield -70.56% · Earnings yield -7.14%

Superinvestors (SEC 13F-HR, Q2 2026) (RCKT)

1 of 80 tracked investors hold RCKT. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Insider sales (SEC Form 4, open-market, last ~7 months) (RCKT)

0 of 15 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (RCKT)

Consensus Hold (mean 2.57 on a 1–5 scale), 14 analysts; mean target USD 8.58 (low 2.95, high 15).

Rating changes, last 120 days:

Total return (dividends reinvested) (RCKT)

Companies that name RCKT in their SEC reports

RCKT company outlook (results filed Aug 10, 2026)

• “Based on its current operating plan, Rocket expects its cash, cash equivalents and investments as of June 30, 2026, to fund operations into the second quarter of 2028.”

Quoted word-for-word from the SEC 8-K results press release.

RCKT analyst estimates and revisions

RCKT options: expected move

Options price a move of about ±31.8% (±$0.73) by Jan 15, 2027, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±5% on average.

30-day implied volatility 79% vs 72.1% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 14:20 UTC)

Technical Analysis (RCKT)

Nexqual's technical model rates RCKT "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of October 23, 2026 at 14:20 UTC.

Analyst Ratings (RCKT)

Wall Street analysts rate RCKT "Hold" based on 14 analysts, with a mean price target of USD 8.58 (range USD 2.95–15), per Nexqual as of October 23, 2026 at 14:20 UTC.

Earnings (RCKT)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 14:20 UTC.

Financials & Fundamentals (RCKT)

Source: Nexqual, October 23, 2026 at 14:20 UTC.

Financial Health Score (RCKT)

Nexqual rates Rocket Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 14:20 UTC.

Ownership (RCKT)

Source: Nexqual, October 23, 2026 at 14:20 UTC.

Leadership (RCKT)

Rocket Pharmaceuticals, Inc. is led by Gaurav D. Shah, CEO & Director, per Nexqual as of October 23, 2026 at 14:20 UTC.

Major Backers & Investors (RCKT)

Notable institutional backers of Rocket Pharmaceuticals, Inc. include RTW Investments LP, Citigroup Inc., Marshall Wace LLP, according to Nexqual as of October 23, 2026 at 14:20 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 14:20 UTC.

From Rocket Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Our platform is supported by in-house research and development capabilities and current cGMP manufacturing facilities that enable end-to-end control of clinical production, process development, and scale-up for potential commercialization.
• We also rely on trade secrets relating to our proprietary technology platform and on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of gene therapy that may be important for the development of our business.
• We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and third parties.
• As consideration for the licensed rights, we paid Licensors an initial upfront license fee of €0.03 million (approximately $0.04 million), which was expensed as research and development costs.

Partnerships

• Based on the initial efficacy observed in the low dose cohort and to mitigate complement-mediated safety concerns observed in the high dose cohort (related to thrombotic microangiopathy or TMA) and in agreement with the FDA, the Phase 2 study was initiated at the low dose (6.7e13 gc/kg).
• Per agreement with the FDA and EMA, engraftment leading to bone marrow restoration exceeding a 10% mitomycin-C resistance threshold could support a marketing application for approval.

Legal & Regulatory Risks (Item 1A, quoted)

• Risks Related to Clinical Development of our Product Candidates
• Risks Related to Government Regulation
• Regulatory requirements governing gene therapy products have evolved and may continue to change in the future.
• Regulatory authorities in some jurisdictions, including the U.S., EU and other major markets, may designate drugs intended to treat conditions or diseases affecting relatively small patient populations as orphan drugs.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 14:20 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt